Administration of insulin like growth factor I (IGFI) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease.
Atherosclerotic cardiovascular disease
IGF-I
IGF-treatment
Lipoprotein(a)
Journal
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
ISSN: 1532-2238
Titre abrégé: Growth Horm IGF Res
Pays: Scotland
ID NLM: 9814320
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
05
03
2023
revised:
26
06
2023
accepted:
20
07
2023
medline:
31
8
2023
pubmed:
21
8
2023
entrez:
20
8
2023
Statut:
ppublish
Résumé
Insulin like growth factor I (IGFI) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered.
Identifiants
pubmed: 37598644
pii: S1096-6374(23)00026-6
doi: 10.1016/j.ghir.2023.101548
pii:
doi:
Substances chimiques
Growth Hormone
9002-72-6
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Lipoprotein(a)
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101548Informations de copyright
Copyright © 2023. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest No conflicts of interest.